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The Challenge of the Unknown Known*Richard R.P. Warner, MD,y Javier G. Castillo, MDzSEE PAGE 2189C arcinoid tumors are rare (2.5 to 5.0 cases per100,000 of the population per year), slow-growing neuroendocrine malignancies with
signiﬁcant potential to produce hepatic metastases
and release excessive amounts of vasoactive amines
into the systemic circulation (1). As a consequence,
up to 15% of patients may develop carcinoid syn-
drome, with cutaneous ﬂushing, gastrointestinal
hypermotility, and cardiac involvement. Cardiac man-
ifestations, also known as carcinoid heart disease
(CaHD), are caused by endocardial deposition of
pearly ﬁbrotic plaques (notable for absence of elastic
ﬁbers) that generally extend to the right-sided valves,
leading to multiple patterns of severe valve dysfunc-
tion. Plaque formation causes annular constriction,
leaﬂet thickening, and fusion of the subvalvular appa-
ratus. Marked degeneration of the leaﬂet architecture
leads to severe retraction and noncoaptation of the
valve, which remains ﬁxed in a semiopen position
(2). In this setting, valve replacement is the only deﬁn-
itive treatment to potentially mitigate symptoms,
provide survival beneﬁt, and improve quality of life.
Cardiac surgery for CaHD traditionally has been
reserved for patients with symptomatic right ven-
tricular (RV) failure because of its inherent prohibitive
perioperative mortality; however, recent series have
documented a signiﬁcant trend toward improved
outcomes, which consequently has triggered a more
liberal surgical referral (3). Poor functional class and*Editorials published in the Journal of the American College of Cardiology
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outcomes, so much so that surgery is currently indi-
cated unless an imminent demise is anticipated,
especially if liver metastases are amenable to surgical
resection. In this context, perioperative management
of patients with CaHD may pose 2 challenges: the
potential acute onset of a carcinoid crisis (vasodila-
tion, cardiac arrhythmias, bronchospasm, and facial
hyperemia) and the identiﬁcation and management of
low cardiac output syndrome (hemodynamically sig-
niﬁcant RV failure vs. profound hypotension second-
ary to severe systemic vasodilation vs. terminal
metastatic disease).In this issue of the Journal, Connolly et al. (4)
introduce the largest series to date of surgical
patients with CaHD. The authors, academically
proﬁcient in this complex ﬁeld, update the Mayo
Clinic experience after scrutinizing the medical re-
cords of 195 consecutive patients who underwent
multivalve surgery during a 27-year period (1985
to 2012). This retrospective study analyzed medical
and surgical trends, perioperative outcomes, long-
term follow up, and referral patterns. From a critical
point of view, there are 3 major points that deserve
further attention, because they will potentially
become decision-making tenets: 1) the surgical man-
agement of right-sided CaHD should routinely consist
of valve replacement and subsequent enlargement of
the RV outﬂow tract; 2) there is a clear trend toward
signiﬁcantly improved perioperative outcomes and
survival, which will probably impact management
and referral patterns in the very near future; and
3) a comprehensive multidisciplinary assessment of
tumor burden and cardiac status (introduction of
new imaging tools and more accurate biomarkers)
is critical in guiding optimal timing of surgery in
patients with carcinoid syndrome and CaHD.
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2198The most common primary site of carcinoid tumors
is the gastrointestinal tract (60%); one-third of them
(34%) arise in the small intestine, and up to 75% of
these may metastasize to the liver (5). Resection of
the primary carcinoid tumor and the hepatic metas-
tases when feasible is routinely recommended in all
patients with carcinoid syndrome. However, in the
setting of CaHD, severe tricuspid regurgitation may
lead to hepatic venous outﬂow obstruction, signiﬁ-
cant elevation of post-sinusoidal pressures, visceral
engorgement, and pulsatile liver. In this scenario,
identiﬁcation of resectable hepatic metastases in pa-
tients with severe CaHD should prioritize and prompt
cardiac surgery over any hepatic intervention.
As described in the paper by Connolly et al. (4),
valve replacement should be the procedure of choice
to treat right-sided lesions, mainly on the basis of 2
axioms: 1) the presence of severe leaﬂet ﬁbrosis and
thickening, as well as fusion of the subvalvular
apparatus, makes repair either unfeasible or not du-
rable; and 2) the potential impossibility of effectively
eliminating or at least reducing the levels of circu-
lating vasoactive amines (disease progression in pa-
tients with uncontrolled or refractory disease) favors
valve replacement. Although tricuspid valve
replacement has been habitually accepted by most
authors, the need for pulmonary valve replacement
has remained debatable. In this regard, although
many patients may certainly tolerate some degree of
pulmonary regurgitation (as reported, pulmonary
valvectomy was once preferred over replacement),
Connolly et al. (4) observed incomplete RV remodel-
ing in patients with long-standing overload. In
addition, a more uneventful post-operative recovery
has been seen among those patients undergoing
concomitant pulmonary valve replacement. There-
fore, the authors recommend pulmonary valve
replacement and concomitant enlargement of the RV
outﬂow tract to accommodate a larger prosthesis.
This has been our institutional routine at Mount
Sinai; however, some European institutions still
advocate the use of homografts in the pulmonary
position. According to the data described by Connolly
et al. (4) and per our own experience, the use of ho-
mografts may not be optimal for several reasons: 1)
constriction of the homograft may lead to early valve
dysfunction; 2) homograft calciﬁcation and subse-
quent stiffening may exclude patients from having
future percutaneous interventions with a consequent
risk of potential rupture after balloon inﬂation; and 3)
homografts might be more amenable to plaque
deposition and recurrent CaHD (6).
The most incendiary debate among carcinoid ex-
perts is the choice of prosthesis at the time of valvereplacement. Historical series have favored the use of
mechanical prostheses on the basis of likely early
structural valve deterioration caused by high levels of
vasoactive substances and the relatively young age of
patients. However, as emphasized in the paper by
Connolly et al. (4), the literature has progressively
supported the use of bioprostheses based on multiple
key points: 1) patients receiving bioprostheses have
better short-term outcomes; 2) survival rarely exceeds
current valve durability (69%, 35%, and 24% at 1, 5,
and 10 years, respectively); 3) patients with CaHD
often present with abnormal liver proﬁles and sec-
ondary coagulopathies; 4) long-term or chronic use of
vitamin K antagonists may represent an additional
risk in patients who will surely undergo multiple
subsequent procedures or receive chemotherapy;
and 5) pathology review of explanted bioprostheses
has proved that carcinoid involvement of the bio-
prosthesis is uncommon (only found in a single
explanted valve vs. valve thrombosis in the rest).
Regarding the latter point, the present report advo-
cates the use of post-operative vitamin K antagonists
3 months after surgery and then periodic echocar-
diographic surveillance (the authors noted the reversal
of bioprosthetic dysfunction after initiation of anti-
coagulation). We also adopted this protocol 1 year ago
and have experienced similar results. Yet unpublished
data have suggested some degree of bioprosthetic
dysfunction in approximately 20% of patients (unclear
pathogenesis, recurrent carcinoid vs. thrombosis).
The ﬁrst report on the surgical management of
CaHD was published in 1963, but it was not until the
early 1990s that the ﬁrst surgical series were pub-
lished. In 1995, an analysis of the Duke Carcinoid
Database observed an operative mortality rate as high
as 63% (7). That same year, Connolly et al. (8) re-
ported the initial Mayo Clinic experience, with an
overall operative mortality rate of 35%. A decade
later, Møller et al. (9) updated the Mayo Clinic expe-
rience and demonstrated a more important decline in
perioperative mortality (16% in a series of 87 pa-
tients). Since then, several European series have
shown 30-day mortality rates below 20%, with opti-
mistic short-term outcomes (10,11). In the present
study, Connolly et al. (4) observed an overall opera-
tive mortality rate of 10%. Interestingly, this rate was
much lower when patients were divided according to
different study periods (17% before 2000 vs. 6% after
2000). In our own experience with 32 patients, the
mortality rate also dropped, from 20% to 9%, if
analyzed according to different study periods (12). We
strongly believe that as with every complex surgical
procedure, knowledge about the disease and volume
highly impact outcomes (Figure 1).
FIGURE 1 Operative Mortality Trends in Patients Undergoing Surgery for Carcinoid Heart Disease According to Surgical Volume and
Study Period
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2199The proliﬁc development of somatostatin ana-
logues, the introduction of new lines of therapy such as
tryptophan hydroxylase inhibitors (i.e., telotristat
etiprate), and the wider application of new diagnostic
tools (i.e., gallium-68 positron emission tomography
computed tomography) have resulted in better control
of carcinoid symptoms and therefore an improved
survival in patients with metastatic disease. Thus,
referral timing for valve replacement will deﬁnitely be
the nextmajor research focus in CaHD. The presence of
severe symptomatic CaHD (patients with New York
Heart Association functional class III to IV or moderate
to severe RV dysfunction) has been shown to increase
perioperative mortality (9). Additionally, according to
the present study, the era of operation (a surrogate for
a wider acquired knowledge of the disease and better
patient selection, as well as the implementation of
new, reﬁned procedural techniques) and the use of
intravenous loop diuretic therapy (a surrogate for
advanced congestive heart failure) were independent
predictors of surgical mortality. It seems prudent to
advance the clock and consider surgical intervention
in those asymptomatic patients with progressive
RV dilation or dysfunction or before liver resection
or transplantation. To revisit surgical indications,
2 different schools of thoughts have proposed the useof new echocardiographic techniques (ventricular
strain) or biomarkers (brain natriuretic peptide) for RV
screening in asymptomatic patients (13). However,
although we tend to use the former as an indicator, we
believe that themost efﬁcient screening tool or marker
for early detection of RV failure or dilation in patients
with CaHD is yet to come.
Finally, in this pioneering series with long-term
survival analysis, it is important to highlight that
advanced New York Heart Association functional class
(symptoms) was identiﬁed as a predictor of decreased
long-term survival in univariate analysis. In other
words, presymptomatic surgical intervention corre-
lated not only with better surgical outcomes but also
with better long-term survival. Although this survival
beneﬁt was not observed in multivariate analysis
(as opposed to age, tobacco use, and pre-operative
chemotherapy), we concur with the authors that this
might be a reﬂection of tumor burden on life expectancy.
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